 |
|
|
| |
European Phase 3/3b Experience With Long-Acting Cabotegravir
and Rilpivirine: Efficacy, Safety, and Virologic Outcomes
|
| |
| |
EACS 2021 Oct 27-30
Jean-Michel Molina1, M. Luisa Montes2, Stefan Esser3, Nathalie De Castro1, Parul Patel4, Samia Dakhia5, Joseph W. Polli4, Louise Garside6, Ronald D'Amico4, Christine Talarico4, Veerle Van Eygen7, Kati Vandermeulen7, William R. Spreen4, Michael Aboud5, Matthew Bosse8
1University of Paris Diderot, Saint-Louis Hospital, Paris, France; 2La Paz University Hospital, Madrid, Spain; 3University Hospital Duisburg-Essen, Germany; 4ViiV Healthcare, Research Triangle Park, NC, United States; 5ViiV Healthcare, Brentford, United Kingdom;
6GlaxoSmithKline, London, United Kingdom; 7Janssen Research & Development, Beerse, Belgium; 8ViiV Healthcare, San Diego, CA, United States
|
| |
|
|
|
|
|
